FeesSafety
Pluang+

IceCure's U.S. sales jump 83% in 9 months, revenue up 26%, but losses widen amid clinical delays.

Company Fundamentals
18 Nov 2026, 22:13 WIB
The Motley Fool
View Source
Bullish
IceCure's U.S. sales jump 83% in 9 months, revenue up 26%, but losses widen amid clinical delays.

IceCure Medical reported a 26% revenue increase to $2.6 million for the first nine months of 2026, driven by an 83% surge in U.S. sales of its ProSense tumor-freezing system. The company expanded its U.S. commercial presence from 11 to 21 states, enhancing sales and clinical support. However, clinical trial enrollment is delayed due to slow contract negotiations, impacting timelines. Despite a $12.9 million operating loss, management expects continued revenue growth with a focus on pricing and physician engagement to support long-term adoption.

IceCure Medical's recent revenue growth is context for readers interested in health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Nov 19, 2026 02:21 WIB: Among 150 priced US health-sector stocks, 71 rose and 78 fell. Notable movers include UNH at USD 347.35 with a 10.86% decline and 88% sell order activity, FLNA at USD 0.53 up 10.21% but with 100% sell orders, and WGS at USD 51.65 up 9.21% with 99% sell orders.

More News

Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb increased its full-year 2026 earnings guidance following a 12% revenue growth in its growth portfolio to $7.7 billion, driven by eight medicines each generating over $1 billion annually. The company is offsetting losses from pate...

Company Fundamentals
Bullish
55 minutes ago
Restaurant Brands posts strong Q3 sales growth, international expansion, and improved debt ratings.

Restaurant Brands posts strong Q3 sales growth, international expansion, and improved debt ratings.

Restaurant Brands reported 6.2% systemwide sales growth and 6.7% organic operating income growth in Q3 2026, driven by Burger King's U.S. same-store sales rising 8.4% and Popeyes expanding to over 2,000 international locations with $2 billion in sale...

Company Fundamentals
Bullish
55 minutes ago
Silgan plans to split into two companies after acquiring Trivium, raising full-year EPS forecast.

Silgan plans to split into two companies after acquiring Trivium, raising full-year EPS forecast.

Silgan announced it will acquire Trivium and separate into two independent packaging companies: Silgan Dispensing Solutions, focusing on high-growth dispensing products, and Silgan Metal Container Corporation, specializing in food packaging. Despite ...

Company Fundamentals
Bullish
55 minutes ago
Gladstone Capital's net investment income rises to $11M in Q4 2026, driven by equity gains and variable rate loans.

Gladstone Capital's net investment income rises to $11M in Q4 2026, driven by equity gains and variable rate loans.

Gladstone Capital reported net investment income of $11 million for Q4 fiscal 2026, supported by a focus on lower middle market lending and disciplined credit terms. The company’s equity investments generated $64.2 million in gains over five years, o...

Company Fundamentals
Bullish
1 hour ago
Voyage revenues soar 249% in Q3 2026 as C3is expands fleet and boosts earnings.

Voyage revenues soar 249% in Q3 2026 as C3is expands fleet and boosts earnings.

C3is reported a 249% increase in voyage revenues to $16.7 million for Q3 2026, driven by higher charter rates and a larger fleet including two new product tankers. The company achieved a 1,300% rise in adjusted net income for the first nine months, r...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App